Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.
Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB.

Estimated time to complete: 0.25 hours

Start date: November 7, 2024
End date: November 6, 2025

This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG).

To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ 


Activity Faculty
Richard J. Nowak, MD, MS
Director, Program in Clinical & Translational Neuromuscular Research (CTNR) 
Director, Yale Myasthenia Gravis Clinic 
Associate Professor of Neurology 
Division of Neuromuscular Medicine
Department of Neurology 
Yale School of Medicine 
New Haven, CT

Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. 

Learning Objectives
After participating in the activity, learners should be better able to
Describe the role of FcRn in MG.

Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other HCPs
Other members of the care team will receive a certificate of participation.

Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:

Faculty Educator
Dr. Nowak discloses the following relevant financial relationships with ineligible companies:
Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCB
Grant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCB

Planners for this activity have no relevant financial relationships with any ineligible companies.

This activity will review off-label or investigational information. 

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of...